[ad_1]
Data from early experiments showed that the emerging coronavirus vaccine, developed by the University of Oxford in Great Britain, produces a strong immune response in the elderly, who are among the groups most at risk of developing complications from the epidemic .
The results of the first and second stages of the trials indicate that the elderly can develop strong immunity, according to data published in the medical journal “Lancet.”
This comes a day after Pfizer announced the effectiveness of the Corona vaccine, which it developed in partnership with the company “Biontech”, in 94 percent among people over 65 years.
The American company “Moderna” has also announced that the effectiveness of its vaccine is close to 95%.
Approximately 560 healthy adult volunteers participated in the second phase of the Oxford trials, where they were given two doses of the vaccine that was being developed, while others received a placebo.
The report adds that no harmful health problems were reported during the trials, according to “Sky News.”
The University of Oxford says that, in most cases, the elderly tend not to respond to vaccines and develop the necessary immunity just like younger adults, since the antibodies that are stimulated by the vaccine often show a less protection capacity.
“The elderly are a priority group for the Covid-19 vaccine, because they have a higher risk of developing severe disease, but we know they have a weak response to vaccines,” said researcher and consultant physician to the Oxford Vaccine Group, Mahshi Ramasamy. .
He added: “We are pleased to see that not only were the elderly able to tolerate our vaccine, but it also stimulated immune responses similar to those seen in younger volunteers. The next step will be to see if this translates into protection against the disease itself.”
Trials of the third phase of the Oxford vaccine, which will determine the effectiveness of the vaccine, are still ongoing and results are expected in the coming weeks.
Studies indicate that the Oxford vaccine will not need to be stored at lower temperatures, as is the case with the Pfizer and Moderna vaccines.
The head of the Oxford vaccine testing team, Professor Andrew Pollard, said: “There is no competition between different vaccines, because we need several vaccines to be successful, since we have many people who need protection around the world.”
"); //}, 3000);}}); //$(window).bind('scroll '); $ (window) .scroll (function () {if (alreadyLoaded_facebookConnect == false) {alreadyLoaded_facebookConnect = true ; // $ (window) .unbind ('scroll'); // console.log ("scroll loaded"); (function (d, s, id) {var js, fjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = id; js.async = true; js._https = true; js.src = "https://connect.facebook.net/en_US/all.js#xfbml=1&appId=148379388602322"; fjs.parentNode.insertBefore (js, fjs); } (document, 'script', 'facebook-jssdk')); // pre_loader (); // $ (window) .unbind ('mousemove'); // setTimeout (function () {// $ ('# boxTwitter'). html ("Tweets from @tayyar_org"); //}, 3000); var scriptTag = document.createElement (" script "); scriptTag.type =" text / javascript "scriptTag.src =" https://news.google.com/scripts/social. js "; scriptTag.async = true; document.getElementsByTagName (" head ")[0].appendChild (scriptTag); (function () {$ .getScript ("https://news.google.com/scripts/social.js", function () {});}); }}); //$(window).load(function () {// setTimeout (function () {// // add the returned content to a newly created script tag // var se = document.createElement ('script'); / / se.type = "text / javascript"; // //se.async = true; // se.text = "setTimeout (function () {pre_loader ();}, 5000);"; // document. getElementsByTagName ('body')[0].appendChild (se); //}, 5000); //});
[ad_2]
